These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 30128744)

  • 21. Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn's disease.
    Jongsma MME; Vuijk SA; Cozijnsen MA; van Pieterson M; Norbruis OF; Groeneweg M; Wolters VM; van Wering HM; Hojsak I; Kolho KL; van Wijk MP; Teklenburg-Roord STA; de Meij TGJ; Escher JC; de Ridder L
    Eur J Pediatr; 2022 Aug; 181(8):3055-3065. PubMed ID: 35672586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exclusive enteral nutrition versus corticosteroids for treatment of pediatric Crohn's disease: a meta-analysis.
    Yu Y; Chen KC; Chen J
    World J Pediatr; 2019 Feb; 15(1):26-36. PubMed ID: 30666565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exclusive enteral nutrition with concomitant early thiopurine use was effective in maintaining steroid-free remission in a Southeast Asian cohort of children with Crohn's disease.
    Ong C; Lim PT; Logarajah V; Liwanag MJ; Ang BX; Cher Y; Chiou FK; Kader A
    BMC Gastroenterol; 2018 Dec; 18(1):185. PubMed ID: 30541458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of exclusive enteral nutrition on body composition and circulating micronutrients in plasma and erythrocytes of children with active Crohn's disease.
    Gerasimidis K; Talwar D; Duncan A; Moyes P; Buchanan E; Hassan K; O'Reilly D; McGrogan P; Edwards CA
    Inflamm Bowel Dis; 2012 Sep; 18(9):1672-81. PubMed ID: 22069243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease.
    Swaminath A; Feathers A; Ananthakrishnan AN; Falzon L; Li Ferry S
    Aliment Pharmacol Ther; 2017 Oct; 46(7):645-656. PubMed ID: 28815649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
    Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
    Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
    García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
    J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach.
    Day AS; Whitten KE; Lemberg DA; Clarkson C; Vitug-Sales M; Jackson R; Bohane TD
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1609-14. PubMed ID: 16928225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effectiveness of induction therapy with exclusive enteral nutrition in pediatric Crohn's disease].
    Luo YY; Fang YH; Yu JD; Xu LJ; Sun MF; Cheng Q; Chen J
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jun; 24(6):626-630. PubMed ID: 35762427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exclusive enteral nutritional therapy can relieve inflammatory bowel stricture in Crohn's disease.
    Hu D; Ren J; Wang G; Li G; Liu S; Yan D; Gu G; Zhou B; Wu X; Chen J; Ding C; Wu Y; Wu Q; Liu N; Li J
    J Clin Gastroenterol; 2014 Oct; 48(9):790-5. PubMed ID: 24440935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Exclusive Enteral Nutrition and Corticosteroid Induction Therapy on the Gut Microbiota of Pediatric Patients with Inflammatory Bowel Disease.
    Hart L; Farbod Y; Szamosi JC; Yamamoto M; Britz-McKibbin P; Halgren C; Zachos M; Pai N
    Nutrients; 2020 Jun; 12(6):. PubMed ID: 32517036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
    Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
    Dig Dis Sci; 2017 Nov; 62(11):3123-3130. PubMed ID: 28948412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decline in presumptively protective gut bacterial species and metabolites are paradoxically associated with disease improvement in pediatric Crohn's disease during enteral nutrition.
    Gerasimidis K; Bertz M; Hanske L; Junick J; Biskou O; Aguilera M; Garrick V; Russell RK; Blaut M; McGrogan P; Edwards CA
    Inflamm Bowel Dis; 2014 May; 20(5):861-71. PubMed ID: 24651582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of Remission With Exclusive Enteral Nutrition in Children With Crohn's Disease: Determinants of Higher Adherence and Response.
    Cuomo M; Carobbio A; Aloi M; Alvisi P; Banzato C; Bosa L; Bramuzzo M; Campanozzi A; Catassi G; D'Antiga L; Di Paola M; Felici E; Fioretti MT; Gatti S; Graziano F; Lega S; Lionetti P; Marseglia A; Martinelli M; Musto F; Sansotta N; Scarallo L; Zuin G; Norsa L
    Inflamm Bowel Dis; 2023 Sep; 29(9):1380-1389. PubMed ID: 36222487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
    Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
    Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn's disease patients.
    Foster AJ; Smyth M; Lakhani A; Jung B; Brant RF; Jacobson K
    World J Gastroenterol; 2019 Mar; 25(10):1266-1277. PubMed ID: 30886509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nationwide Real-World Exclusive Enteral Nutrition Practice Over Time: Persistence of Use as Induction for Pediatric Crohn's Disease and Emerging Combination Strategy With Biologics.
    Wands DIF; Gianolio L; Wilson DC; Hansen R; Chalmers I; Henderson P; Gerasimidis K; Russell RK
    Inflamm Bowel Dis; 2024 Aug; 30(8):1258-1263. PubMed ID: 37619221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Impact of Compliance During Exclusive Enteral Nutrition on Faecal Calprotectin in Children With Crohn Disease.
    Mckirdy S; Russell RK; Svolos V; Gkikas K; Logan M; Hansen R; Gerasimidis K
    J Pediatr Gastroenterol Nutr; 2022 Jun; 74(6):801-804. PubMed ID: 35192573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of exclusive enteral nutrition in complicated Crohn's disease.
    Yang Q; Gao X; Chen H; Li M; Wu X; Zhi M; Lan P; Hu P
    Scand J Gastroenterol; 2017 Sep; 52(9):995-1001. PubMed ID: 28598298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.